OPHLY:OTCMKTS
Ono Pharmaceutical ADR Representing 1/3rd Ord Shs
4,98 $
arrow_upward
+1,12%(+0,055) 1D
16 հոկ, 16:00:00 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for OPHLY...
Open
5,05 $
High
5,07 $
Low
4,98 $
Mkt. cap
1,20 տրլն
Avg. vol.
62,80 հզր
Volume
20,91 հզր
52-wk high
5,75 $
52-wk low
3,82 $
Beta
0,21
Shares outstanding
1,50 մլրդ
No. of employees
4 հզր
Open
5,05 $
High
5,07 $
Low
4,98 $
Mkt. cap
1,20 տրլն
Avg. vol.
62,80 հզր
Volume
20,91 հզր
52-wk high
5,75 $
52-wk low
3,82 $
Beta
0,21
Shares outstanding
1,50 մլրդ
No. of employees
4 հզր
News stories
From web sources and news partners
The Motley Fool
·
20 րոպե առաջ
Missing the S&P 500's 10 Best Days in 20 Years Cut a $10,000 Investment's Ending Value by More Than Half
ChartMill
·
37 րոպե առաջ
HONGLI GROUP INC (NASDAQ:HLP) Passes Minervini Trend Template and High-Growth Momentum Screen
Simply Wall Street
·
1 ժամ առաջ
Mobile Wallet Payouts Change The Bull Case For DLocal (DLO)
MarketWatch
·
12 ժամ առաջ
Don’t buy this dip: Several signs suggest there’s more pain ahead for tech stocks
Profile
Ono Pharmaceutical Co., Ltd. is one of the largest pharmaceutical companies in Japan. It is headquartered in Chuo-ku, Osaka, Japan, with its major plants in Higashinari-ku, Osaka, and Fujinomiya, Shizuoka., and its central research institute at Minase, Shimamoto-cho, Mishima District, Osaka.
Ono Pharmaceutical's roots go back to 1717 when Ichibei Ono started his dealer business of pharmaceuticals in Osaka. His business expanded and changed its name a few times, and became Ono Pharmaceutical Industrial Co., Ltd. in 1948.
Ono has been listed in Tokyo Stock Exchange since 1963. Its consolidated earnings in the half year ending in March 2018 were 16 billion Japanese yen.
Nivolumab, the cancer drug based on the research of Prof. Dr. Tasuku Honjo of Kyoto University, who received the Nobel Prize later in 2018, is marketed by both Ono Pharmaceutical and Bristol-Myers Squibb.
In 2024, Harvard University and Ono Pharmaceutical entered into a joint research and drug development agreement. Under it, promising projects to test therapeutic targets will be selected over 5 years under the guidance of Harvard's Office of Technology Development, and ONO will fund the work. Wikipedia
About Ono Pharmaceutical ADR Representing 1/3rd Ord Shs
CEOGyo Sagara | Gyo Sagara
Employees4,21 հզր
Founded1717
HeadquartersՕսակա, Osaka, Ճապոնիա
Sector-
Websiteono-pharma.com